Flutafuranol

Summary

Flutafuranol (CHEMBL2048308) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 258.25 Da · C14H11FN2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2048308
Name	Flutafuranol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	24896605
Molecular formula	C14H11FN2O2
Molecular weight	258.25
InChIKey	MYNQXTDIPMCJCR-UHFFFAOYSA-N

SMILES: CNC1=NC(=C(C=C1)C2=CC3=C(O2)C=CC(=C3)O)F

IUPAC name: 2-[2-fluoro-6-(methylamino)-3-pyridinyl]-1-benzofuran-5-ol

Also known as: Azd-4694, AZD4694

Parent form; salt/anhydrous children: CHEMBL2048315, CHEMBL2158614

Patent coverage: 18 distinct patent families (43 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Amyloid-beta precursor protein.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
APP	7.62	IC50	24	nM	CHEMBL_ACT_10948311

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).